ReviewPharmacoEconomics2013
Cabazitaxel for the second-line treatment of metastatic hormone-refractory prostate cancer: a NICE single technology appraisal.
Ben Kearns et al.PubMed ↗Publisher ↗
No numbers read from the abstract.
28 papers cite it
this paperpooled itcites it